Replies to post #107559 on Biotech Values

[turtlepower]

It's misleading because it didn't clearly state what the drug is approved for in NYTimes while it is in Bloomberg:

From Bloomberg:

The medicine, Nuedexta, is the first approved to treat patients with multiple sclerosis or Lou Gehrig’s disease who develop symptoms known as pseudobulbar affect that causes loss of emotional control, the Food and Drug Administration said in a statement.

From nytimes. I think the times was clearer :)

It is laughter devoid of inner joy, and weeping without sorrow.

Involuntary outbursts of laughing and crying not tied to underlying emotion can afflict people with neurological ailments like multiple sclerosis, Lou Gehrig’s disease, traumatic brain injury and stroke.

Now there is a drug for it. On Friday, the Food and Drug Administration approved the first medicine to treat the condition, which is called pseudobulbar affect.

[DewDiligence]

AVNR—[NYT article is] misleading because it didn't clearly state what the drug is approved for…

I may be nitpicking here, but the FDA label for Nuedexta does not explicitly restrict use to patients with MS/ALS; rather, the label merely states that the studies supporting approval were conducted in patients with MS/ALS.

From a reimbursement standpoint, the above distinction may not matter; however, I think you were unduly critical of the NYT article in #msg-56108000 when you accused it of misstating the approved indication.